CGTX
NASDAQ
US
Cognition Therapeutics, Inc. - Common Stock
$0.87
▼ $-0.02
(-2.58%)
Vol 1.0M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$119.2M
ROE
-150.1%
D/E
0.00
Beta
1.30
52W
$0–$4
Wall Street Consensus
10 analysts · Apr 20262
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
90.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 40.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.09 | $-0.05 | +$0.04 |
| Sep 2025 | $-0.10 | $-0.06 | +$0.04 |
| Jun 2025 | $-0.11 | $-0.11 | $0.00 |
| Mar 2025 | $-0.11 | $-0.14 | $-0.03 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$9.9M | -$7.8M | -$8.5M | -$6.7M | -$4.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -251.2% | -251.2% | -251.2% | -251.2% | -150.1% | -150.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.58 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.54 | 1.54 | 1.54 | 1.54 | 6.44 | 6.44 |
Key Ratios
ROA (TTM)
-95.9%
P/B
1.6
EPS (TTM)
$-0.48
CF/Share
$-0.79
52W High
$3.83
52W Low
$0.22
$0.22
52-Week Range
$3.83
Financial Health
Free Cash Flow
-$5.7M
Net Debt
-$39.0M
Cash
$39.3M
Total Debt
$380K
As of Sep 30, 2025
How does CGTX compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
CGTX valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
1.6
▼
27%
below
peers
(2.1)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
CGTX profitability vs Pharmaceuticals peers
ROE
-150.1%
▼
177%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-95.9%
▼
156%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
CGTX financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
6.4
▲
92%
above
peers
(3.4)
vs Peers
vs Industry
Below avg
Beta
1.3
▲
38%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
CGTX fundamentals radar
CGTX
Peer median
Industry
CGTX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CGTX vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
RICCIARDI LISA
Chief Executive Officer · Feb 03
800000 shs
DOYLE JOHN BRENDAN
Chief Financial Officer · Feb 03
200000 shs
CAGGIANO ANTHONY
Officer · Feb 03
400000 shs
Last 90 days
Top Holders
Top 5: 16.09%Bios Capital Management, LP…
6.80%
$4.4M
Vanguard Group Inc
3.76%
$2.4M
Davenport & Co LLC
3.25%
$2.1M
Blackrock Inc.
1.15%
$741K
Chescapmanager LLC
1.13%
$728K
As of Dec 31, 2025
Latest News
No related news yet